Today, On 17th October, The Supreme Court dismissed Roche’s appeal challenging the Delhi High Court’s refusal to restrain Natco Pharma from producing Risdiplam for Spinal Muscular Atrophy, observing it would not interfere since the High Court’s concurrent findings were interim in nature.
The Supreme Court asked the Centre to reply to a plea for help for the daughter of an Indian Air Force official suffering from Spinal Muscular Atrophy (SMA) Type 1. This rare genetic disease weakens muscles and affects movement, needing costly treatment. The plea stresses the need for government support. SMA Type 1 severely impacts infants and young children.